Global Dengue Vaccines Market Overview:
Dengue is a viral disease transmitted by infected mosquitoes, particularly female mosquito of Aedes aegypti responsible vector to transmit the virus that causes dengue. Dengue causes sudden fever and pain in the joints. While vaccines are preventive measures taken to cure any disease by facilitating immunity to develop protection from disease. It is a biological preparation that provides active acquired immunity, vaccines are consisting of substance-related to disease-causing microorganism and are sometimes made from weak or killed forms of the microbe, its toxins, or its proteins. Dengue vaccine is mainly CYD tetravalent dengue vaccine from Sanofi Pasteur (France)is leading for dengue vaccines. A live attenuated vaccine known as Dengvaxia, developed by Sanofi, launched and approved license in 2015. Dengvaxia is a mixture of four monovalent chimeric vaccine viruses, CYD-1, CYD-2, CYD-3, and CYD-4, produced using Vero cells. These four CYDs are based on the yellow fever virus (YFV) 17D vaccine vector backbone. First licenses approved in Mexico in 2015 for 9-45 individuals for 20 countries. Some of the key players profiled in the study are Sanofi Pasteur Inc (France), Merck & Co Inc (United States), GlaxoSmithKline (United Kingdom ), Pfizer (United States), Instituto Butantan (Brazil), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Limited (India), GeneOne Life Science Inc (South Korea), Medigen Vaccine Biologics Corporation (China) and Merck Sharp & Dohme (United States).
On the basis of geography, the market of Dengue Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Government organizations will boost the Dengue Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Vaccines, the sub-segment i.e. Live Attenuated Vaccines will boost the Dengue Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Demand due to Rising in Infection Level
- Two New Live Attenuated Dengue Vaccines Are Currently In Phase Iii Efficacy Trials
- Dsv4 Process Development And Scale-Up Work Are Currently In Progress
- The Lack Of An Appropriate Animal Model That Elucidates The Pathogenesis, Immune Response And Clinical Course Of Dengue Infection In Humans
- Unsuitable For Studying Immune Responses In Dengue Vaccine Pre-Clinical Trials
- Sometimes Side Effects Related To Dengue Vaccines Are Severe
- Highly Demanded In Rainy Season
- Dengue Vaccines Are Challenged By Critical Issues Like Lack Of Animal Models For The Disease And Absence Of Suitable Markers Of Protective Immunity
- New Advances In Dengue Pathogenesis And Immune Response Will Shed Light On The Approach Needed To Make An Ideal Dengue Vaccine
- Dengue Vaccines Banned In Philippines Due To Controversy
Major Market Developments:
In January 2020 Sanofi Completes Acquisition of Synthorx, Inc. Synthorx, Inc. is now a fully owned subsidiary of Sanofi. Sanofi announced the successful completion of its acquisition of Synthorx, Inc. (Synthorx) for USD 68 per share in cash. The acquisition of Synthorx perfectly aligns R&D strategy, enhancing the position of Sanofi as an emerging leader in the area of oncology and immunology.
On January 28, 2020, The FDA has accepted for Priority Review the supplemental Sanofiís Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The target action date for the FDA decision is May 26, 2020. Dupixent would be the first biologic medicine available in the U.S. for these children
On 1st May 2019, the FDA approves the first vaccine for dengue fever, but with major restrictions. The Food and Drug Administration approved the first vaccine against dengue fever, one that protects against a common disease but has generated significant controversy due to evidence it can increase the risk of severe infection in some people. Dengvaxia was licensed in 2015. But it caused a major scandal two years ago in the Philippines. After nearly a million Filipino children had been vaccinated with Dengvaxia, the drug's manufacturer, Sanofi, announced that the inoculation might make dengue worse in some people.
The leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines. Therefore the competition is now with research teams of different manufactures to get the company profit and business. There is also an option available like mergers and acquisitions of a different firm to enhanced the research and technological enhancement of the companies.
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Clinical Trial Centres and Downstream Vendors
Major Objectives Focused through this Study
To define, describe, and forecast the Global Dengue Vaccines market on the basis of product  , application [Prevention of dengue and Enhanced the immunity], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Dengue Vaccines market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Dengue Vaccines industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Vabiotec (Vietnam) and Panacea Biotec Limited (India).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Dengue Vaccines market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.